Please provide your email address to receive an email when new articles are posted on . There were no differences in most CVD outcomes over more than 2 decades between three antihypertensive agents.
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia Two-year HCT survivors treated at a comprehensive cancer center from 1992 through 2009 who were ...
Surgical and conservative management show similar impacts on CV risk and mortality in bilateral adrenal tumors and cortisol excess.
A nationwide Finnish cohort study evaluated long-term mortality, morbidity, recovery, and stroke recurrence following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results